Skip to main content
Search form
Search
Medicines for Malaria Venture
Developing antimalarials to save lives
Research & Development
MMV's pipeline of antimalarial drugs
R&D areas of work
Next-generation medicines
Products for key populations
Working with regulators
Information for scientists
Malaria online course
Global health compound design webinars
Call for proposals
TPPs & TCPs
Learning resources for scientists
Project of the year award
Computational chemistry
R&D challenges
Access
Products & projects
Antimalarial drug availability
Areas of work
Supporting introduction
Enhancing reach
Informing R&D
Gathering market intelligence
Antimalarial drug toolkits
Artesunate injection dosage & administration
Artesunate rectal capsules tool kit
Seasonal Malaria Chemoprevention tool kit
Access challenges
Partnering
The PDP model
Our partner network
Our donors
Current donors
Past donors
Donate to MMV
Intellectual property rights (IPR)
Clinical centre partners by country
Our impact
Milestones
Malaria stories from the field
Antimalarial drugs for children
Gender equity
Global health security
Antimicrobial resistance to antimalarials
Malaria and COVID-19
About us
What we do
An overview of our work
Our strategic focus
Our history
People & governance
Staff bios
Staff interviews
Board of Directors
MMV North America Board
Expert Scientific Advisory Committee
Access & Product Management Advisory Committee
Global Safety Board
Work with us
Jobs
RFPs/RFIs
Policies
Diversity at MMV
Funding and expenditure
FAQs
Contact us
Malaria & medicines
Definitions and symptoms
5 species of
Plasmodium
parasites
Lifecycle of malaria parasite
Malaria facts & statistics
Malaria treatment
History of antimalarial drugs
Newsroom
News & Press Releases
Audio
Media interviews
Speaking of Malaria podcast
Films
Infographics
Interviews
Image slideshows
Publications
Events
MMV Open
The Global Health Priority Box
About the Global Health Priority Box
Supporting information
Request the Global Health Priority Box
Terms & conditions
Malaria
Libre
Malaria
Libre
open innovation platform
Participate in Malaria
Libre
Malaria
Libre
data repository
MMVSola
About MMVSola
Pandemic Response Box
About the Pandemic Response Box
Request the Pandemic Response Box
Supporting information
Terms & conditions
COVID Box
About the COVID Box
Supporting information
COVID Box terms and conditions
Archived projects
Pathogen Box
Malaria Box
MMV Open Team
Contact us
Home
Newsroom
Press releases
Press releases
Filter
All
R&D
Donors
General
Open source
Partner
Access & product management
All
R&D
Donors
General
Open source
Partner
Access & product management
162 found
Medicines for Malaria Venture and the Africa CDC sign Memorandum of Understanding to support African manufacturers
15 Dec 2022
Strong Recommendation for Pyronaridine-Artesunate in Revised WHO Malaria Treatment Guidelines
25 Nov 2022
Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria
23 Nov 2022
First African-manufactured medicine to prevent malaria in pregnant women and infants quality-approved by WHO
25 Aug 2022
MMV and IVCC make 240 compounds available to stimulate research into new drugs and insecticides
13 Aug 2022
Single-dose Kozenis (tafenoquine) approved for children with
Plasmodium vivax
malaria by Australian Therapeutic Goods Administration
14 Mar 2022
Novartis and Medicines for Malaria Venture report positive results for Phase IIb study of novel ganaplacide/lumefantrine combination in children with malaria
29 Sep 2021
New partnership launched to accelerate elimination of relapsing
P. vivax
malaria that poses a risk to an estimated 2.5 billion people worldwide
14 Jul 2021
Pyronaridine-artesunate demonstrates high real-life safety, tolerability and effectiveness in the treatment of uncomplicated malaria in large multi-country study in Africa
17 Jun 2021
This World Malaria Day MMV recognizes Swiss Malaria Group's commitment to defeating malaria
19 Apr 2021
New report demonstrates how R&D partnerships serving neglected communities have developed dozens of life-saving innovations since 2010
28 Jan 2021
GSK, MMV filing for Kozenis (tafenoquine) in paediatric populations with
Plasmodium vivax
malaria accepted by Australian Therapeutic Goods Administration
08 Jan 2021
MMV supports the launch of the new Fight the Fakes Alliance
07 Dec 2020
Largest clinical trial in Africa to treat COVID-19 cases before they become severe
20 Nov 2020
GSK and MMV present positive data on treatment of
Plasmodium vivax
malaria
19 Nov 2020
Endemic countries in South America meet to discuss new tools for malaria elimination
02 Nov 2020
Global call to boost access to lifesaving malaria treatment for pregnant women in Africa
15 Oct 2020
MMV launches the COVID Box to stimulate new drug research
10 Jun 2020
This World Malaria Day MMV supports Swiss Malaria Group's call for urgent action
25 Apr 2020
Thailand becomes first malaria-endemic country in Asia-Pacific to approve tafenoquine for radical cure of
P. vivax
malaria
24 Apr 2020
MMV and LSTM collaborate to fill data gap on use of antimalarials during pregnancy
08 Mar 2020
International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa
03 Mar 2020
Research for new drugs against neglected diseases and malaria in Brazil to receive funding boost totaling BRL 43.5 million
27 Nov 2019
Country leaders pledge to boost malaria innovation and access to new and existing antimalarials
11 Nov 2019
Brazil becomes first malaria-endemic country to approve single-dose tafenoquine (Kozenis) for radical cure of
P. vivax
malaria
30 Oct 2019
Life-saving malaria project in Zambia to expand
25 Apr 2019
PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria
23 Apr 2019
Europe-Africa partnership spearheads development of next-generation antimalarial drug
15 Apr 2019
MMV and DND
i
make 400 compounds available to stimulate research into new drugs for pandemic diseases
29 Jan 2019
Two positive phase III studies of tafenoquine for the radical cure of
Plasmodium vivax
malaria published in The New England Journal of Medicine
16 Jan 2019
World Malaria Report highlights importance of country-led efforts to defeat malaria in highest burden countries
19 Nov 2018
Kozenis (tafenoquine) approved by the Australian Therapeutic Goods Administration for the radical cure of
P. vivax
malaria
21 Sep 2018
Severe malaria case fatality reduced by 96% in pilot project in Zambia led by Transaid, MMV and partners
28 Aug 2018
US FDA approves
Krintafel
(tafenoquine) for the radical cure of
P. vivax
malaria
20 Jul 2018
US FDA Advisory Committee endorses the effectiveness and safety of single-dose tafenoquine for the radical cure of
P. vivax
malaria
12 Jul 2018
WHO provides first-ever approval for rectal artesunate product for severe malaria
27 Feb 2018
GSK submits US regulatory application for single-dose tafenoquine for
Plasmodium vivax
malaria
28 Nov 2017
KAF156 enters phase IIb combination studies
21 Aug 2017
Cipla launches quality-assured Rectal Artesunate Suppositories for severe malaria in young children
25 Jul 2017
Three MMV-supported antimalarials listed as essential medicines
16 Jun 2017
MMV and GSK announce positive headline phase III results showing single-dose tafenoquine reduces risk of relapse in patients with
Plasmodium vivax
malaria
12 Jun 2017
MMV and Zydus join forces to develop new antimalarial
27 Sep 2016
UCT-H3D, MMV and international partners identify second potent antimalarial candidate
27 Jul 2016
MMV and Novartis expand partnership
15 Jun 2016
MMV joins Swiss Malaria Group in Bern to commemorate World Malaria Day
25 Apr 2016
Netherlands-based consortium teams up with MMV in world-leading malaria translational research programme
25 Apr 2016
Pyramax® granules (pyronaridine-artesunate) for children added to WHO list of prequalified medicines
20 Apr 2016
MMV announces collaborative agreement with S Kant HEALTHCARE Ltd
10 Mar 2016
Pyramax® Granules becomes first paediatric antimalarial to receive EMA Article 58 positive scientific opinion
20 Nov 2015
MMV provides QIMR Berghofer AU$10 M for malaria drug development
08 Nov 2015
GHIT invests $10.7 million in malaria, TB, leishmaniasis and dengue research
05 Nov 2015
New study details safety and efficacy of re-treatment with Pyramax®
23 Oct 2015
New compound has the potential to treat malaria patients in a single dose
17 Jun 2015
GHIT, Takeda and MMV progress first-in-class antimalarial DSM265 to patient trials in Peruvian Amazon
05 Jun 2015
Merck Serono and MMV sign agreement to develop potential antimalarial therapy
01 Apr 2015
Japanese global health fund announces new investment in promising compounds for antimalarial drug discovery
05 Feb 2015
Independent Safety Monitoring Board assessment enables recruitment of 2-5 year olds into OZ439/PQP Phase IIb trial
20 Jan 2015
MMV announces collaborations with Cipla and Strides
27 Nov 2014
GSK and MMV announce start of Phase III programme of tafenoquine
28 Apr 2014
Potential new antimalarial drug identified at the University of Dundee
06 Feb 2014
Pages
1
2
3
next ›
last »